AllPennyStocks.com Biotech Soars On Material Transfer Agreement

Biotech Soars On Material Transfer Agreement

Biotech Soars On Material Transfer Agreement By: Tomas Ronolski - AllPennyStocks.com News

Tuesday, September 24, 2024

A New York-based biotech company is turning heads on Tuesday after it announced it signed a material transfer agreement to supply SLS-002 for the Department of Defense’s military and veterans adaptive platform clinical trial for PTSD.

Traders were quick to snatch up shares of Seelos Therapeutics Inc. (Nasdaq:SEEL), pushing the price of this micro cap up to $0.5536/share (+191.37%) at the early session high. This move  could be indicative of a potential breakout for this stock in sessions to come!

Seelos Therapeutics Inc is a clinical-stage biotechnology company. The company is focused on developing products that address significant unmet needs in the Central Nervous System (CNS) disorders and other rare disorders.


Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Canada’s Inflation Rate Hits Central Bank Target
Tech Shares Pop Following Acquisition Announcement
Biotech Soars On Material Transfer Agreement
Most Popular


Back to Top